Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2018

View Archived Issues

XW Laboratories initiates phase I study of XW-10172 for narcolepsy

Sosei regains rights to CGRP antagonist programs from Teva

Identification of novel locus for idiopathic dilated cardiomyopathy in African Americans

MB-66 vaginal film shows HIV, HSV neutralizing activity in phase I study

Patient enrollment begins in phase III study of favipiravir for thrombocytopenia syndrome

Reduced adverse effect potential demonstrated with Mebias Discovery's mu-opioid receptor agonists

Researchers present data on mRNA-based vaccine for HIV-1 infection

AbbVie gains rights to discovery programs from X-Chem

Bellicum Pharmaceuticals reports encouraging interim data from clinical trial of BPX-501

Shionogi launches Xofluza in Japan

Ideaya Biosciences, CRUK enter partnership to develop PARG inhibitors

Intra-Cellular Therapies plans rolling NDA submission for lumateperone

AbCellera Biologics receives DARPA contract for rapid countermeasures against viral outbreaks

Ardelyx divulges novel FXR agonists

Boehringer Ingelheim and Vanderbilt University expand cancer collaboration

New IDO1 inhibitors presented by InnoCare Pharma

Kadimastem cleared to conduct phase I/IIa study of ALS treatment

Second pivotal phase III study of AbbVie's elagolix meets primary endpoint

Escalier Biosciences closes series B financing

Protalix Biotherapeutics' OPRX-106 produces clinical response in study in ulcerative colitis

FDA accepts sBLA for Keytruda in advanced cervical cancer with priority review

Eight-week grazoprevir/elbasvir treatment shown effective against HCV infection

Phanes partners with Crown Bioscience to advance oncology drug discovery pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...